---
document_datetime: 2025-02-14 13:37:32
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/lyumjev-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: lyumjev-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 3.7852943
conversion_datetime: 2026-01-22 21:28:07.151238
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.69.0
  docling-core: 2.60.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Lyumjev

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                           |
|----------------------|--------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------|
| PSUSA/1755/ 202404   | Periodic Safety Update EU Single assessment - insulin lispro | 16/01/2025                          | n/a                                         |                                  | PRAC Recommendation - maintenance |
| R/0019               | Renewal of the marketing authorisation.                      | 14/11/2024                          | 13/01/2025                                  | SmPC and PL                      |                                   |
| IB/0018              | B.II.f.1.b.5 - Stability of FP - Extension of the shelf      | 24/04/2024                          | 13/01/2025                                  | SmPC                             |                                   |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|         | life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |            |             |                                                                   |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------|
| IB/0017 | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 13/02/2023 | n/a        |             |                                                                   |
| II/0014 | Extension of indication to include the treatment of diabetes mellitus in adolescents and children aged 1 year and above, based on final results from study I8B-MC-ITSB; this is a pivotal Phase 3 study designed to evaluate the safety and efficacy of Lyumjev compared to Humalog in combination with basal insulin in children and adolescent patients with T1D. The study was designed to compare change in HbA1c as the primary endpoint. As a consequence, sections 4.1, 4.2, 4.8, 5.1, and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to implement update minor editorial and linguistic changes in the SmPC and Package Leaflet. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | 13/10/2022 | 18/11/2022 | SmPC and PL | Please refer to Scientific Discussion 'Lyumjev-H-C-5037-II- 0014' |
| II/0016 | B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 17/11/2022 | n/a        |             |                                                                   |

<div style=\"page-break-after: always\"></div>

|                    | biological AS                                                                                                                                                                                                                                                 |            |            |             |                                                                                                                                                                                                                                                                                                                                        |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0015            | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                 | 23/05/2022 | n/a        |             |                                                                                                                                                                                                                                                                                                                                        |
| X/0010             | Annex I_1.(c) Replacement of a biological AS with one of a slightly different molecular structure                                                                                                                                                             | 24/02/2022 | 25/04/2022 |             |                                                                                                                                                                                                                                                                                                                                        |
| PSUSA/1755/ 202104 | Periodic Safety Update EU Single assessment - insulin lispro                                                                                                                                                                                                  | 02/12/2021 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                      |
| IA/0013            | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                  | 25/08/2021 | n/a        |             |                                                                                                                                                                                                                                                                                                                                        |
| IA/0012            | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                  | 25/08/2021 | n/a        |             |                                                                                                                                                                                                                                                                                                                                        |
| N/0009             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                              | 09/06/2021 | 25/04/2022 | PL          |                                                                                                                                                                                                                                                                                                                                        |
| II/0008/G          | This was an application for a group of variations. Update of sections 4.8 and 5.1 of the SmPC in order to update clinical information based on final results from study Study I8B-MC-ITRO (PRONTO-Pump-2); this is a Phase 3 prospective, randomized, double- | 11/02/2021 | 21/04/2021 | SmPC and PL | The information regarding infusion site reactions in the SmPC and PL was updated in SmPC 4.8. The update in SmPC 5.1on efficacy of Lyumjev in study ITRO (aka PRONTO-Pump-2) reflects the non-inferiority of Lyumjev in overall glycaemic control and superiority in control of postprandial glucose excursions compared with Humalog, |

<div style=\"page-break-after: always\"></div>

|                    | blind trial, which compared Lyumjev to Humalog in adults with Type 1 Diabetes using continuous subcutaneous insulin infusion. The Package Leaflet is updated accordingly. The MAH also provides a phase 2 study evaluating Lyumjev in a Medtronic Pump (Study I8B-MC-ITSM) as a grouped variation. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |            |                        | also when used as CSII.                                                                                                                                                                |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0006/G          | This was an application for a group of variations. B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.IV.z - Quality change - Change in Medical Devices - Other variation                                                                                                                                                                                                                                          | 11/02/2021 | 21/04/2021 | SmPC, Labelling and PL | Sections 1, 2, 4.2, 4.4, 6.4, 6.5, 6.6 and 8 of the SmPC were updated in order to add the new pre-filled pen presentations; the Package Leaflet and Labelling are updated accordingly. |
| II/0005            | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 21/01/2021 | 21/04/2021 | SmPC                   |                                                                                                                                                                                        |
| PSUSA/1755/ 202004 | Periodic Safety Update EU Single assessment - insulin lispro                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 26/11/2020 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                      |
| IB/0007            | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP -                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 19/10/2020 | n/a        |                        |                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|           | Replacement/addition of a site where batch control/testing takes place                                                                                                                         |            |            |                        |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| IB/0003   | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation | 26/08/2020 | 21/04/2021 | SmPC and PL            |
| IB/0002   | B.II.f.1.a.3 - Stability of FP - Reduction of the shelf life of the finished product - After dilution or reconstitution                                                                        | 30/06/2020 | 21/04/2021 | SmPC and PL            |
| IAIN/0001 | A.2.a - Administrative change - Change in the (invented) name of the medicinal product for CAPs                                                                                                | 10/04/2020 | 21/04/2021 | SmPC, Labelling and PL |